The Cancer Drugmaker That Beat the Odds — Then Ran Out of Cash
Published November 9, 2026
Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, after its approved blood-cancer drug Xpovio never sold enough to cover its costs: about $115 million in 2025 sales against $196 million in losses and a $1.8 billion accumulated deficit. Ayrmid, parent of cell therapy maker Gamida Cell, is the lead bidder in a court-supervised auction, and the prepackaged plan cancels existing shares with no payout while lenders take over the reorganized company.
On November 2, 2026, Karyopharm Therapeutics, a cancer drugmaker based in Newton, Massachusetts, filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas. It was a filing with an uncomfortable twist: Karyopharm had already done the hardest thing in biotechnology — it had brought a medicine to market — and it still ran out of money. Ayrmid, the parent of cell therapy maker Gamida Cell, stepped in as the lead bidder in a court-supervised auction, and the company said the acquisition should close in early 2027.
The company's story was built around selinexor, an oral drug that blocks a protein called exportin 1, sold in the United States under the brand name Xpovio. The drug was first approved in 2019 for multiple myeloma, a blood cancer, and later cleared for a common form of lymphoma. Approval is the dream of every small biotech, and Karyopharm achieved it. But approval is not the same as a business: in its 2025 annual report, the company recorded about $115 million in net Xpovio sales against $196 million in losses, with an accumulated deficit of $1.8 billion. It warned at that point that it had only enough cash and revenue to stay afloat through the middle of 2026.
What went wrong was the slow grind of commercial reality. The company had hoped that expanding Xpovio's approved uses would grow sales, but the drug failed a clinical trial in endometrial cancer, and a decision on using it in myelofibrosis was still months away — the company filed for that approval in August 2026 and expected to hear around November 10 whether regulators would even accept the application. Meanwhile, about $15.8 million in debt was coming due, and the company missed payments on its term loan and second-lien notes, part of roughly $390 million in funded debt. A forbearance agreement with lenders bought a little time, then ended.
The market's verdict arrived the same day as the filing: Karyopharm's shares fell 83 percent to just 11 cents apiece, giving the whole company a market value of only about $2.5 million. It held $55 million in cash and equivalents as of June 30. Under the prepackaged plan agreed with creditors, the company's existing common and preferred shares would be cancelled with no payment to holders, while the lenders who financed the company take ownership of the reorganized business and merge it with Ayrmid, receiving 55 percent of the combined company plus rights tied to future myelofibrosis sales.
The deal is not a liquidation. Ayrmid's chief executive, Joe Wiley, said adding Xpovio to Gamida Cell's line of blood cancer cell therapies could build a broader, stronger commercial-stage hematology business, and that the combined company would keep delivering therapies to patients. Karyopharm continues to operate during the proceedings with the help of a $55 million bankruptcy loan from its current lenders, and the plan already has the support of all of its funded-debt creditors.
The lesson is one biotech investors learn the expensive way: getting a drug approved is only half the battle. A medicine can work, patients can need it, and the company can still fail if the revenue never covers the research and the debt that paid for it. Karyopharm beat the scientific odds and lost to the commercial ones — a reminder that in drug development, the valley of death does not end at approval.
The lesson: Getting a drug approved is only half the battle — a company still has to sell enough of it to pay its debts.
Source: original reporting · How we source stories